According to a news release posted on the official website of the U.S. Food and Drug Administration (FDA) on October 15, leaders from the National Institutes of Health (NIH) and FDA emphasized the importance of advancing research and development for smoking cessation treatments in a new commentary published in the Annals of Internal Medicine. The authors of the article updated regulatory pathways for smoking cessation treatments and outlined innovative treatment targets, research gaps, and development opportunities. They stressed the crucial role of active participation from clinical physicians, academia, industry, public health agencies, patient groups, and other stakeholders.
Data shows that nearly 500,000 people die from smoking in the United States each year, with over 28 million adults smoking in the country. While most smokers express a desire to quit, only 31% of those intending to quit actually seek counseling or medication treatment. The success rate for quitting smoking each year is less than 8%.
The commentator proposed solutions to these issues, including recommendations from the FDA 2023 Nicotine Replacement Therapy guidelines. In order to inspire innovation in smoking cessation product development, the commentator suggested that in smoking cessation trials, in addition to focusing on abstinence, meaningful endpoints should also be considered, such as clinically significant reduction in smoking, especially if this reduction increases the likelihood of eventual cessation.
The authors also emphasized the urgent need for more in-depth research on e-cigarettes, including long-term health outcomes and rigorous toxicology studies. They also discussed programs being conducted by the NIH and FDA aimed at promoting innovative research on smoking cessation, particularly targeting underrepresented groups in historical research trials.
This commentary was released prior to the joint public meeting of the FDA and NIH on advancing smoking cessation priorities, which is scheduled to take place on October 21 from 9:00 AM to 4:30 PM (Eastern Time).
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
